Currently Recruiting Clinical Trials: ACE-083

Do you have CMT1 or CMTX?


Acceleron Pharma has initiated a Phase 2 clinical study of ACE-083,

an investigational drug, in patients with Charcot-Marie-Tooth (CMT) disease.

Click on the recruiting location near you to enroll.


University of California-Irvine
Orange, California 92868
Contact: Jeanette Overton
Phone: 714-456-8520
Email: [email protected]
Principal Investigator: Tahseen Mozaffar, MD


University of Kansas Medical Center – Neurology Department
Kansas City, Kansas, 66160
Contact: Ayla McCalley, CRC
Phone: 913-945-9937
Email: [email protected]
Principal Investigator: Jeffrey Statland

New York

University of Rochester Medical Center, Neurology
Rochester, New York, 14642
Contact: Janet Sowden
Phone: 585-275-1267
Email: [email protected]
Principal Investigator: David N Herrmann, MD


University of Utah
Salt Lake City, Utah, 84112
Contact: Bryant Gordon, CRC
Phone: 801-585-5052
Email: [email protected]
Principal Investigator: Nicholas Johnson, MD


University of Florida
Gainesville, Florida, 32610
Contact: Amanda Cowsert, CRC
Phone: 352-294-8778
Email: [email protected]
Principal Investigator: Sankarsubramoney Subramony, MD


University of Minnesota, Neurology Department
Minneapolis, Minnesota, 55455
Contact: Natalya Burlakova
Email: [email protected]
Principal Investigator: David Walk, MD


Oregon Health & Science University
Portland, Oregon, 97239
Contact: Diana Dimitrova, PhD
Phone: 503-494-7269
Email: [email protected]
Principal Investigator: Chafic Karam, MD


University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Contact: Nicole Kressin
Phone: 319-358-8596
Email: [email protected]
Principal Investigator: Michael Shy, MD

New Jersey

Hackensack University Medical Center
Hackensack, New Jersey, 07601
Contact: Christine Cavallo
Phone: 551-996-3079
Email: [email protected]
Principal Investigator: Florian Thomas, MD


University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Contact: Sonya A Zaman
Email: [email protected]
Principal Investigator: Colin Quinn, MD